SIETES :: 92610 citas

Resultados de la búsqueda por HEROÍNA REFINAR BÚSQUEDA

1.

Hedegaard H, Bastian BA, Trinidad JP, Spencer M, Warner M. Drugs most frequently involved in drug overdose deaths: United States, 2011–2016. National Vital Statistics Reports 2018;67:12 de diciembre. [Ref.ID 102871]

2.

Strang L, Taylor J. Heroin-assisted treatment and supervised drug consumption sites: experience from four countries. Rand Corporation, Santa Monica, California 2018:5 de diciembre. [Ref.ID 102861]

3.

Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2017.. NCHS Data Brief 2018;329:1-8. [Ref.ID 102855]

4.

Lembke A, Papac J, Humphreys K. Our other prescription drug problem. N Engl J Med 2018;378:22 de febrero. [Ref.ID 102557]

5.

Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants — United States, 2015–2016. Morbidity and Mortality Weekly Report 2018;67:30 de marzo. [Ref.ID 102488]

6.

Socías ME, Wood E. Epidemic of deaths from fentanyl overdose. BMJ 2017;359:j4355. [Ref.ID 102107]

7.

O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden M. Deaths involving fentanyl, fentanyl analogs, and U-47700 — 10 states, July–December 2016. Morbidity and Mortality Weekly Report 2017;66:1-5. [Ref.ID 102103]

8.

Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf 2017;26:1083-7. [Ref.ID 102063]

9.

Manhapra A, Rosenheck R. Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. BMJ 2017;357:j1947. [Ref.ID 101635]

10.

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. [Ref.ID 101634]

11.

Gaither JR, Leventhal JM, Ryan SA, et al.. National trends in hospitalizations for opioid poisonings among children and adolescents, 1997 to 2012. JAMA Pediatrics 2016:31 de octubre. [Ref.ID 100870]

12.

Middleton J, McGrail S, Stringer K. Drug related deaths in England and Wales. BMJ 2016;355:i5259. [Ref.ID 100851]

13.

Anónimo. DEA Issues carfentanil warning to police and public dangerous opioid 10,000 times more potent than morphine and 100 times more potent than fentanyl . Drug Enforcement Administration DEA 2016:1. [Ref.ID 100718]

14.

Nuijten M, Blanken P, van de Wetering B, Nuijen B, van den Brink W. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet 2016;387:2226-34. [Ref.ID 100335]

15.

McCarthy M. US needs $1.1bn to treat opioid addiction. BMJ 2016;352:i694. [Ref.ID 100047]

16.

Anónimo. Clarification: half-life of heroin. Med Lett Drugs Ther 2016;58:1. [Ref.ID 100015]

17.

Rudd RA, Aleshire N, Zibbell JE, Gladden M. Increases in drug and opioid overdose deaths — United States, 2000–2014. MMWR Morb Mortal Wkly Rep 2015;64:1-5. [Ref.ID 99739]

18.

Anónimo. Prescription painkiller deaths fall for first time In 15 years. DIA Daily 2014:15 de octubre. [Ref.ID 98097]

19.

Anónimo. Intranasal naloxone for treatment of opioid overdose. Med Lett Drugs Ther 2014;56:21-2. [Ref.ID 97422]

20.

Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, Wagner X, Kiefer F, Hermann D. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol 2013;69:2021-5. [Ref.ID 96638]